262 related articles for article (PubMed ID: 16286517)
1. Effect of orlistat in obese patients with binge eating disorder.
Golay A; Laurent-Jaccard A; Habicht F; Gachoud JP; Chabloz M; Kammer A; Schutz Y
Obes Res; 2005 Oct; 13(10):1701-8. PubMed ID: 16286517
[TBL] [Abstract][Full Text] [Related]
2. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial.
Grilo CM; Masheb RM; Salant SL
Biol Psychiatry; 2005 May; 57(10):1193-201. PubMed ID: 15866560
[TBL] [Abstract][Full Text] [Related]
3. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial.
Svendsen M; Rissanen A; Richelsen B; Rössner S; Hansson F; Tonstad S
Obesity (Silver Spring); 2008 Feb; 16(2):327-33. PubMed ID: 18239640
[TBL] [Abstract][Full Text] [Related]
4. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
5. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
[TBL] [Abstract][Full Text] [Related]
7. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
[TBL] [Abstract][Full Text] [Related]
10. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
11. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
Erdmann J; Lippl F; Klose G; Schusdziarra V
Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
[TBL] [Abstract][Full Text] [Related]
13. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
Elfhag K; Finer N; Rössner S
Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
[TBL] [Abstract][Full Text] [Related]
14. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder.
Devlin MJ; Goldfein JA; Petkova E; Jiang H; Raizman PS; Wolk S; Mayer L; Carino J; Bellace D; Kamenetz C; Dobrow I; Walsh BT
Obes Res; 2005 Jun; 13(6):1077-88. PubMed ID: 15976151
[TBL] [Abstract][Full Text] [Related]
15. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as.
Grilo CM; White MA
Behav Res Ther; 2013 Mar; 51(3):167-75. PubMed ID: 23376451
[TBL] [Abstract][Full Text] [Related]
16. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
[TBL] [Abstract][Full Text] [Related]
17. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
[TBL] [Abstract][Full Text] [Related]
18. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
19. Effects of orlistat on obesity-related diseases - a six-month randomized trial.
Guy-Grand B; Drouin P; Eschwège E; Gin H; Joubert JM; Valensi P
Diabetes Obes Metab; 2004 Sep; 6(5):375-83. PubMed ID: 15287931
[TBL] [Abstract][Full Text] [Related]
20. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]